RESUMO
The triathlon is one of the fastest developing sports in the world due to expanding participation and media attention. The fundamental change in Olympic triathlon races from a single to a multistart event is highly demanding in terms of recovery from and prevention of exercise-induced muscle injures. In elite and competitive sports, ultrastructural muscle injuries, including delayed onset muscle soreness (DOMS), are responsible for impaired muscle performance capacities. Prevention and treatment of these conditions have become key in regaining muscular performance levels and to guarantee performance and economy of motion in swimming, cycling and running. The aim of this review is to provide an overview of the current findings on the pathophysiology, as well as treatment and prevention of, these conditions in compliance with clinical implications for elite triathletes. In the context of DOMS, the majority of recovery interventions have focused on different protocols of compression, cold or heat therapy, active regeneration, nutritional interventions, or sleep. The authors agree that there is a compelling need for further studies, including high-quality randomized trials, to completely evaluate the effectiveness of existing therapeutic approaches, particularly in triathletes. The given recommendations must be updated and adjusted, as further evidence emerges.
RESUMO
UNLABELLED: There is little information about the actual nutrition and fluid intake habits and gastrointestinal (GI) symptoms of athletes during endurance events. PURPOSE: This study aimed to quantify and characterize energy, nutrient, and fluid intakes during endurance competitions and investigate associations with GI symptoms. METHOD: A total of 221 endurance athletes (male and female) were recruited from two Ironman triathlons (IM Hawaii and IM GER), a half-Ironman (IM 70.3), a MARATHON, a 100/150-km CYCLE race. Professional cyclists (PRO) were investigated during stage racing. A standardized postrace questionnaire quantified nutrient intake and assessed 12 GI symptoms on a scale from 0 (no problem) to 9 (worst it has ever been) in each competition. RESULTS: Mean CHO intake rates were not significantly different between IM Hawaii, IM GER, and IM 70.3 (62 ± 26, 71 ± 25, and 65 ± 25 g·h(-1), respectively), but lower mean CHO intake rates were reported during CYCLE (53 ± 22 g·h(-1), P = 0.044) and MARATHON (35 ± 26 g·h(-1), P < 0.01). Prevalence of serious GI symptoms was highest during the IM races (â¼31%, P = 0.001) compared with IM 70.3 (14%), CYCLE (4%), MARATHON (4%), and PRO (7%) and correlated to a history of GI problems. In all data sets, scores for upper and lower GI symptoms correlated with a reported history of GI distress (r = 0.37 and r = 0.51, respectively, P < 0.001). Total CHO intake rates were positively correlated with nausea and flatulence but were negatively correlated with finishing time during both IM (r = -0.55 and r = -0.48, P < 0.001). CONCLUSIONS: The present study demonstrates that CHO intake rates vary greatly between events and individual athletes (6-136 g·h(-1)). High CHO intake during exercise was related not only to increased scores for nausea and flatulence but also to better performance during IM races.